LLY vs MXCT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
MaxCyte (MXCT) exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating severe financial deterioration. While the company maintains a strong liquidity cushion with a Current Ratio of 8.30 and low debt, these are offset by a massive profit margin of -135.14% and declining year-over-year revenue growth of -16%. Despite a significant gap between the current price ($0.88) and analyst target prices ($4.05), the deterministic data suggests a high-risk profile characterized by a catastrophic 5-year price decline of 94.8%.
Compare Another Pair
Related Comparisons
LLY vs MXCT: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and MaxCyte, Inc. (MXCT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.